Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial

PURPOSE: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA SNPs and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here. PATIENTS AND METHODS:...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Schneider, Bryan P., Gray, Robert J., Radovich, Milan, Shen, Fei, Vance, Gail, Li, Lang, Jiang, Guanglong, Miller, Kathy D., Gralow, Julie R., Dickler, Maura N., Cobleigh, Melody A., Perez, Edith A., Shenkier, Tamara N., Nielsen, Kirsten Vang, Müller, Sven, Thor, Ann, Sledge, George W., Sparano, Joseph A., Davidson, Nancy E., Badve, Sunil S.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594423/
https://ncbi.nlm.nih.gov/pubmed/23340303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3029
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki